DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Effect of Fiasp® in Type 1 Diabetes Treatment

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Fiasp®

First Posted Date: 2019-03-29

Last Posted Date: 2022-04-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 178

Registration Number: NCT03895515

Locations: 🇸🇪
Novo Nordisk Investigational Site, Stockholm, Sweden

A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Liraglutide

First Posted Date: 2019-03-25

Last Posted Date: 2021-07-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 839

Registration Number: NCT03888157

Locations: 🇮🇷
Novo Nordisk Investigational Site, Yazd, Iran, Islamic Republic of

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

Phase 2

Active, not recruiting

Conditions: Short Stature Children Born Small for Gestational Age (SGA)

Interventions: Drug: Norditropin®
Drug: Somapacitan

First Posted Date: 2019-03-18

Last Posted Date: 2025-05-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 62

Registration Number: NCT03878446

Locations: 🇮🇱
Rambam Medical Center Children A Dept., Haifa, Israel
🇮🇹
IRCCS Meyer Firenze, Firenze, Italy
🇮🇹
Bambin Gesù, Roma, Italy

and more 47 locations

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2019-03-15

Last Posted Date: 2021-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 215

Registration Number: NCT03876015

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

Conditions: Haemophilia B

Interventions: Drug: Refixia®

First Posted Date: 2019-03-14

Last Posted Date: 2024-08-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 20

Registration Number: NCT03875547

Locations: 🇩🇰
Novo Nordisk Investigational Site, Søborg, Denmark
🇯🇵
Nagoya University Hospital_Blood Transfusion, Aichi, Japan
🇯🇵
Chiba University Hospital_Diabetes, Metabolism and Endocrinology, Chiba-shi, Chiba, Japan

and more 14 locations

A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BIAsp 30

First Posted Date: 2019-03-05

Last Posted Date: 2020-07-20

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT03862690

Locations: 🇩🇿
Novo Nordisk Investigational Site, Constantine, Algeria

Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.

Phase 2

Completed

Conditions: Overweight
Obesity

Interventions: Drug: NNC0174-0833
Drug: Placebo (NNC0174-0833)
Drug: Placebo (Liraglutide 3.0 mg)
Drug: Liraglutide 3.0 mg

First Posted Date: 2019-02-27

Last Posted Date: 2024-07-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 706

Registration Number: NCT03856047

Locations: 🇺🇸
South Broward Research LLC, Pembroke Pines, Florida, United States
🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸
Texas Diabetes & Endocinology, Round Rock, Texas, United States

and more 50 locations

A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2

Phase 2

Completed

Conditions: Primary Hyperoxaluria Type 2 (PH2)
Genetic Disease
Kidney Diseases
Urologic Diseases
Primary Hyperoxaluria Type 1 (PH1)

Interventions: Drug: Sterile Normal Saline (0.9% NaCl)
Drug: DCR-PHXC

First Posted Date: 2019-02-20

Last Posted Date: 2024-05-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 35

Registration Number: NCT03847909

Locations: 🇬🇧
Clinical Trial Site, London, United Kingdom

A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity

Phase 1

Completed

Conditions: Overweight
Obesity

Interventions: Drug: Semaglutide
Drug: Placebo

First Posted Date: 2019-02-15

Last Posted Date: 2020-12-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 72

Registration Number: NCT03842202

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

A Research Study, Looking at How Xultophy® Works in People With Type 2 Diabetes in Local Clinical Practice in United Arab Emirates

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin degludec/liraglutide

First Posted Date: 2019-01-30

Last Posted Date: 2021-09-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 300

Registration Number: NCT03823339

Locations: 🇦🇪
Novo Nordisk Investigational Site, Dubai, United Arab Emirates

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy